Drug firm Zydus Cadila has launched its generic Tenglyn tablets belonging to new class of oral anti-diabetic treatment drugs, Gliptins, in the Indian market.
Tenglyn is being priced at Rs 7 per tablet which is almost 1/6th the price at which the Gliptins were initially launched in India, to make this therapy affordable and accessible to diabetic patient, Zydus Cadila said in a statement.
Commenting on the development, Zydus Cadila Deputy Managing Director Sharvil Patel said: "Diabetes, as we know, is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost."
At Zydus, the endeavour has been to bring new therapies and innovations that address the two primary challenges inIndia of accessibility and affordability, he added.
The company had earlier launched Lipaglyn (Saroglitazar) in the country in September 2013 for treatment of diabetic dyslipidemia and hypertriglyceridemia, Zydus Cadila said.
Shares of Cadila Healthcare, a listed entity of the Zydus Group today closed at Rs 417.30 per scrip on BSE, up 1.31 per cent from it's previous close.
Tenglyn is being priced at Rs 7 per tablet which is almost 1/6th the price at which the Gliptins were initially launched in India, to make this therapy affordable and accessible to diabetic patient, Zydus Cadila said in a statement.
Commenting on the development, Zydus Cadila Deputy Managing Director Sharvil Patel said: "Diabetes, as we know, is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost."
At Zydus, the endeavour has been to bring new therapies and innovations that address the two primary challenges inIndia of accessibility and affordability, he added.
The company had earlier launched Lipaglyn (Saroglitazar) in the country in September 2013 for treatment of diabetic dyslipidemia and hypertriglyceridemia, Zydus Cadila said.
Shares of Cadila Healthcare, a listed entity of the Zydus Group today closed at Rs 417.30 per scrip on BSE, up 1.31 per cent from it's previous close.
No comments:
Post a Comment